New T cell treatments for childhood cancers
Official title: Next Generation T cell therapies for childhood cancers (NexTGen)
Funded at New York University School of Medicine · NIH-10907163 · Data updated 2026-11-12
This study is working on new treatments using special immune cells to help kids with solid tumors, like certain types of sarcomas and brain tumors, that current therapies often struggle to treat.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 14, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $102,263 |
| NIH project number | 1OT2CA290738-01 |
| Project ID | NIH-10907163 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with solid tumors, particularly sarcomas and brain tumors, who have not responded to existing treatments.
✕Less likely to help
Patients with hematologic malignancies or those whose tumors do not fall within the targeted categories may not benefit from this research.
What this research studies
This research focuses on developing advanced T cell therapies specifically designed for treating solid tumors in children, which current treatments often fail to cure. By utilizing engineered T cells, the project aims to create therapies that can effectively target and combat pediatric solid cancers, overcoming challenges such as tumor heterogeneity and hostile environments. The approach involves detailed studies of primary tumors to identify new targets and understand how the tumor microenvironment affects T cell function, guiding the engineering of more effective T cell therapies. The research is structured into interconnected work packages, initially concentrating on pediatric sarcomas and brain tumors.
Why it matters
Potential benefit: If successful, this research could lead to effective and less toxic treatments for childhood solid cancers, significantly improving survival rates.
How similar studies have gone: While engineered T cell therapies have shown promise in adult cancers, this approach for pediatric solid tumors is relatively novel and untested.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Yarmarkovich, Mark — New York University School of Medicine
- Study coordinator: Yarmarkovich, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.